Abstract
Article Profound decline of antibody titers 6 months after BNT162b2 vaccination in healthy volunteers was published on December 29, 2021 in the journal Journal of Laboratory Medicine (volume 0, issue 0).
Highlights
As of the beginning of October 2021, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 219 million individuals worldwide and caused more than 4.55 million deaths
Levels of IgG and IgM were expressed in arbitrary units (AU)/mL and evaluated in relation to a cut-off index calculated by quantification of standard anti-SARS-CoV-2 receptor-binding domain (RBD) antibody samples
Kozakai et al.: Decline of antibody titers 6 months after BNT162b2 vaccination et al [5] identified a significant trend of declining spike protein antibody levels among individuals vaccinated with both ChAdOx1 nCOV-19 (Oxford/AstraZeneca) and BNT162b2: antibody levels were reduced by about five-fold for ChAdOx1 and by about twofold for BNT162b2 70 days after the second dose
Summary
As of the beginning of October 2021, severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has infected over 219 million individuals worldwide and caused more than 4.55 million deaths. Levels of IgG and IgM were expressed in arbitrary units (AU)/mL and evaluated in relation to a cut-off index calculated by quantification of standard anti-SARS-CoV-2 RBD antibody samples. At the time of writing, all 41 participants have completed 6 months of follow up since the first dose of BNT162b2.
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
